维生素K2 结合钙剂在甲状腺功能亢进症继发骨质 疏松症中的临床应用. (Chinese)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): 董坤伦
  • Source:
    Chinese Journal of Osteoporosis; Feb2018, Vol. 23 Issue 2, p218-221, 4p
  • Additional Information
    • Alternate Title:
      Clinical application of vitamin K2 combined with calcium in secondary osteoporosis of hyperthyroidism. (English)
    • Abstract:
      Objective To investigate the effect of vitamin K2 on bone mineral density,bone metabolism and cytokine levels in patients with hyperthyroidism osteoporosis. Methods 57 patients with hyperthyroidism osteoporosis treated in our hospital from July 2014 to July 2015 were randomly divided into treatment group ( n = 29) and control group ( n = 28) . The control group was treated with calcium,and the treatment group was treated with vitamin K2 combined with calcium for 12 months. Bone mineral density ( BMD) of hip and lumbar spine,bone metabolic index ( BGP,PINP) and cytokines ( IL-2,IL-6 and IGF-1 ) were examined and compared before and after treatment. Results Before treatment,BMD,BGP,PINP,IL-2,IL-6 and IGF-1 of the two groups had no significant differences ( P > 0. 05 ) . After 12 months of treatment,BMD of hip and lumbar spine were significantly higher than those in the control group ( P < 0. 05) ,and the levels of BGP and PINP in the treatment group were significantly lower than those in the control group ( P < 0. 05) . The level of IL-2 in the treatment group was significantly higher than that in the control group ( P < 0. 05) and IL- 6 and IGF-1 levels were significantly lower than those in the control group ( P < 0. 05) . Conclusion Vitamin K2 could significantly improve bone mineral density,reduce bone turnover,increase IL-2 expression and decrease IL-6 and IGF-1 levels in patients with secondary osteoporosis of hyperthyroidism,thus has protective effect to osteoporosis. [ABSTRACT FROM AUTHOR]
    • Abstract:
      目的探讨维生素K2 对甲状腺功能亢进性骨质疏松症患者骨密度、骨代谢指标及细胞因子水平变化的影响。方法 选取2014 年7 月至2015 年7 月来我院治疗的57 例甲状腺功能亢进性骨质疏松症患者作为研究对象,随机分为治疗组( n = 29) 和对照组( n = 28) 。对照组给予钙剂治疗,治疗组给予维生素K2 联合钙剂治疗,为期12 个月。检测所有对象治疗前后髋 部及腰椎的骨密度( bone mineral density,BMD) 、骨代谢指标[骨钙素( osteocalcin,BGP) 和总I 型前胶原氨基端延长肽( total Nterminal propeptide of type I procollagen,PINP) ]以及细胞因子[胰岛素样生长因子-1( insulin-like growth factor, IGF-1) 、白细胞介 素( interleukin, IL) -2、6( IL-2、IL-6) ],并进行比较。结果治疗前,两组患者的BMD、BGP、PINP 及IL-2、IL-6 和IGF-1 比较差 异无统计学意义( P > 0. 05) ; 治疗12 个月后,治疗组髋部及腰椎的BMD 水平显著高于对照组( P < 0. 05) ; 治疗组BGP、PINP 水平显著低于对照组( P < 0. 05) ; 治疗组IL-2 水平显著高于对照组( P < 0. 05) ; 治疗组IL-6 和IGF-1 水平显著低于对照组 ( P < 0. 05) 。结论维生素K2 可以明显提高甲状腺功能亢进性骨质疏松患者的骨密度、降低骨转换,提高IL-2 表达且降低IL- 6 和IGF-1 水平,对骨质疏松有保护作用。 [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)